Point-of-Care CAR T-Cell Therapy Yields 100% ORR in R/R CLL With or Without Richter’s Transformation


The phase 1/2 Euplagia-1 trial is currently ongoing in Europe.

All patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) with or without Richter’s transformation (RT) treated with point-of-care manufactured chimeric antigen receptor (CAR) T-cell therapy GLPG5201 responded in the phase 1/2 Euplagia-1 trial being conducted in Europe.

Data from Euplagia-1 were presented at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany, by Nuria Martínez-Cibrián, MD, Hospital Clinic de Barcelona.

“CLL and SLL remain generally incurable despite advances in treatment, and patients with RT have a poor prognosis. CAR-t therapy has shown durable antitumor responses in a broad range of B-cell malignancies, including CLL and SLL with or without RT,” first author Martínez-Cibrián and colleagues wrote in their poster. “To enable rapid treatment of patients, a standardized, decentralized workflow for fully automated CAR-T manufacturing at the point-of-care has been developed, avoiding complex logistics or cryopreservation.”

WATCH NOW: Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T Therapies

The trial evaluated point-of-care GLPG5201 manufactured by the Lonza Cocoon platform for a 7-day vein-to-vein time in patients with CD19+ R/R CLL after at least 2 prior lines of therapy and no prior CD9-targeted therapy. After leukapheresis and a regimen of daily oral ibrutinib, patients received infusion of either 35x106 (dose level 1 [DL1]) or 100x106 (DL2) CAR T-cells. Three patients had only CLL while 4 had CLL with RT. Patients had a median age of 66 years (range, 58-71) and a median of 3 prior therapies (range, 2-4).

Investigators found that, as of January 2023, all 7 treated patients responded, for an overall response rate of 100%. Of these, 6 patients (86%) had a complete response (CR) and 1 (17%) had a partial response (PR). All patients treated at DL2 had CRs, and the patient with a PR was 1 of 4 treated at DL1. This patient later had a CD19-negative relapse with confirmed RT. Follow-up is ongoing in the study with a current duration of response of up to 7 months.

GLPG5201 was found to have strong expansion in peripheral blood. Looking at safety, no dose-limiting toxicities have been identified and the most common serious adverse events (AE) were hematologic toxicities. No immune-effector cell-associated neurotoxicity syndrome was observed and all cases of cytokine release syndrome were below grade 3, although 1 grade 2 case required intensive care unit admission and was classified as a serious AE. The case resolved after 7 days. A third dose level cohort of 300x106 CAR T-cells is planned

“GLPG5201 is a new CAR-T therapeutic option for patients with R/R CLL with or without RT, showing limited toxicity and promising efficacy based on current results. Phase 1 of the study is ongoing to establish the recommended dose for phase 2,” Martínez-Cibrián and colleagues wrote.

Click here for more coverage of EHA 2023.

Martínez-Cibrian N, Betriu S, Ortiz-Maldonado V, et al. Initial clinical results of Euplagia-1, a phase 1/2 trial of point-of-care manufactured GLPG5201 in R/R CLL/SLL with or without Richter's transformation.Presented at: EHA 2023 Congress. Abstract #P1399
Related Videos
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.